# 3) Countering Emerging Threats Rapid Acquisition and Investigation of Drugs for Repurposing (CET RAIDR)

**R-2A activity** of project MT5 — Mitigate (SDD)  
**Program element:** 0604384BP — Chemical and Biological Defense Program - EMD  
**Component:** Defense-Wide · **Budget Activity:** 5  
**Vintage:** President's Budget PB2027  
**Canonical URL:** https://hitchintel.com/programs/0604384BP/MT5/a2  
**Parent:** https://hitchintel.com/programs/0604384BP/MT5

## Summary

This activity requests $16.5M in FY2027, 37% of project MT5, up 5.1% on FY2026. The R-2A exhibit describes it across FY2025–FY2027, including what the FY2027 money is planned to buy.

## What the FY2027 request buys

**FY2027 planned work.** Field multiple data updates to military medical guidelines to support medical rapid response and maintain force regeneration in a chemical or biological emergency. Continue evaluating FDA-approved and/or late-stage products to repurpose as a CB defense MCM.

**FY2026 to FY2027 change.** Minor increase due to inflation rate adjustment

## Before the request year

**FY2026 plans — current year.** Continue evaluating FDA-approved and/or late-stage products to repurpose as a CB defense MCM. Studies generate safety and efficacy data to support the use of the test product against CB defense symptoms.

**FY2025 accomplishments.** Fielded multiple military medical guidelines to support medical rapid response and maintain force regeneration in a chemical or biological emergency. Continued evaluating FDA approved and/or late-stage products to repurpose to treat symptoms from chemical and biological threats.

## Funding

| Fiscal Year | Estimate Type | Amount ($M) |
|---|---|---|
| FY2025 | Actual | 15.4 |
| FY2026 | Enacted | 15.7 |
| FY2027 | Request | 16.5 |

> Prior, current and budget year only — an R-2A activity carries no five-year plan. It sums exactly into its project in the request year and not necessarily in any other.

## Other activities in project MT5

- 2) Anti-Viral Oral Therapeutics (AVO TX) - Non-Clinical Studies — FY2027 12.5
- 4) Countering Emerging Threats Rapid Acquisition and Investigation of Drugs for Repurposing - Enhanced Biological Defense (CET RAIDR-ENBD) — FY2027 7.5
- 7) Tactical Contamination Mitigation System (TCMS) — FY2027 5.1
- 5) Forward Area Mobility Spray System (FAMS-S) - Aircraft Interior Decon (AID) — FY2027 2.5
- 1) Alternative Autoinjector Manufacturer Capability (AUTOINJ) - RAD-A — FY2027 —
- 6) Service Equipment Decontamination System (SEDS) — FY2027 —
- 8) Improved Nerve Agent Treatment System Centrally Acting (INATS CA) - Non-Clinical — FY2027 —

## Source & machine access

- **Source:** FY2027 Office of the Secretary of Defense RDT&E Budget Justification, Exhibit R-2A, PE 0604384BP project MT5 (PB PB2027). Narrative is the government's own text.
- **No marks, no contractors at this grain** — congressional marks land on the program element and R-3 performers on the project.
- **MCP:** `mcp.hitchintel.com` — `budget_get_activity`.

*HitchAI is an independent intelligence service, not affiliated with the U.S. Department of Defense. Budget figures are requests/estimates, not obligations.*